TG THERAPEUTICS, INC. (TGTX) research
TG THERAPEUTICS, INC.- Sector
- Biotechnology
- Last price
- $54.29
- As of
TG THERAPEUTICS, INC. (TGTX): 7 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 10-Q filed 2026-08-05.
As of . Source: SEC EDGAR filings for TGTX. Method and limitations.
Share the TGTX intelligence card
See the full TGTX dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for TGTX on one page. Preview it with sample data, then open it live with a free account.
Preview the TGTX dossierActive signals for TGTX
- highCONSENSUS_BUY
10 tracked funds increased TGTX this 2026Q2, institutional consensus
- highCONSENSUS_BUY
3 tracked funds increased TGTX this 2026Q2, institutional consensus
- highINSTITUTIONAL_EXIT
Point72 Asset Management, L.P. cut 97% of TGTX (2026Q2)
- highINSTITUTIONAL_EXIT
Point72 Asset Management, L.P. cut 59% of TGTX (2026Q2)
- highINSTITUTIONAL_SURGE
MILLENNIUM MANAGEMENT LLC added +612% to TGTX (2026Q2)
FREE, NO ACCOUNT
Every signal on TGTX, as it fires
You are seeing 5 of 21 signals recorded on TGTX since 2026-05-31.
The five above landed across 2 days. The other 16 were recorded on 3 other days. 14 of the 21 are institutional flow rows, which arrive in batches on filing days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in TGTX (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| D. E. Shaw & Co., Inc.CUSIP 88322Q108 · 2026Q2 | $186.8M | 0.09% | , |
| TWO SIGMA INVESTMENTS, LPCUSIP 88322Q108 · 2026Q2 | $135.6M | 0.10% | , |
| RENAISSANCE TECHNOLOGIES LLCCUSIP 88322Q108 · 2026Q2 | $37.3M | 0.05% | , |
| CITADEL ADVISORS LLCCUSIP 88322Q108 · 2026Q2 | $29.5M | 0.00% | , |
| Bridgewater Associates, LPCUSIP 88322Q108 · 2026Q2 | $23.6M | 0.10% | , |
| MILLENNIUM MANAGEMENT LLCCUSIP 88322Q108 · 2026Q2 | $15M | 0.01% | , |
| Point72 Asset Management, L.P.CUSIP 88322Q108 · 2026Q2 | $14.6M | 0.02% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, TGTX
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
TGTX against its peers
TGTX's operating margin of 20.0% ranks in the 91st percentile of 15 Biotechnology sub-industry peers, fiscal periods ending between 2025-09-30 and 2026-03-31.
| Metric | TGTX | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 616M USD | 190M USD | 64 | 17 |
| Operating margin | 20.0% | -40.4% | 91 | 15 |
| Net margin | 72.6% | -40.4% | 97 | 15 |
| Return on equity | 69.0% | -25.1% | 98 | 20 |
| P / E | 19.6x | n/a | n/a | 4 |
Peers (23): PCVX, PRAX, CAI, CRNX, IBRX, ARWR, CYTK, ABVX, KYMR, PTGX, IONS, SYRE, NUVL, KRYS, APGE, IMVT, RYTM, ALKS, BMRN, BLTE, MDGL, LGND, CNTA. Left out: BCHMY (no annual filing), SBMFF (no annual filing). Fiscal periods ending between 2025-09-30 and 2026-03-31. Every figure is one full fiscal year read from one annual filing (TGTX: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
See more TGTX signals as they fire
Kresmion publishes filings, 13F flows, on-chain whale activity, and cross-asset signals in real time. Open a live board scoped to TGTXand get the insider, 13F, options, and confluence read in one view.